Navigation Links
Vasogen Provides Corporate Update
Date:1/6/2009

MISSISSAUGA, ON, Jan. 6 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN; TSX:VAS) today provided an update on corporate activities. Pursuant to a previously announced restructuring plan, Vasogen has been reviewing strategic alternatives for the purpose of enhancing shareholder value. This process has included screening, reviewing, and short-listing potential opportunities including the sale of the Company, a merger or acquisition, and exploring the monetization of certain tangible and intangible assets. The process has also included a review of the potential out-licensing of assets, asset divestiture, or liquidation of the Company. Vasogen also reported that during this process it has completed a number of initiatives to significantly reduce its base cash burn rate and conserve cash and completed its fiscal year end with over $8.5 million in cash resources.

"While the strategic review process has taken longer than hoped, we continue to be intensely focused on bringing this process to a close," commented Chris Waddick, President and CEO of Vasogen. "Based on our current status, we anticipate being in a position to provide a further update to shareholders before the end of January."

In October 2008, the NASDAQ Stock Market had suspended the enforcement of the rules requiring a minimum $1 closing price until January 20, 2009. Due to the "continued extraordinary market conditions" the NASDAQ has recently extended this suspension. Accordingly, the NASDAQ will not take action to delist any security, including Vasogen's shares, for a violation of the minimum bid price rule during the suspension, which now has been extended until April 20, 2009. Finally, effective December 31, 2008, Mr. Thomas Clarke has retired from Vasogen's Board of Directors. The Company wishes to thank Mr. Clarke for his services.

Certain statements in this documen
'/>"/>

SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... to Date Examined 175,000 Teenage Girls and Adult ... before motherhood,more than doubled in six years among ... study published in the May issue of Diabetes ... looked exclusively at gestational diabetes,(diabetes that develops during ...
... N.J., April 25 Osteotech, Inc.,(Nasdaq: OSTE ), ... for,regenerative medicine, announced today that the United States Food ... the Plexur,P(TM) Biocomposite for use in spinal applications as ... Previously, Osteotech received FDA clearance for,Plexur P(TM) for use ...
... Inc. (Amex: IMA ), a leading manufacturer ... and professional markets, announced,today that it will attend ... held April 30 - May 2, 2008, at ... Executive Officer, will,attend. His presentation is scheduled for ...
Cached Biology Technology:Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 2Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 3Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 4Osteotech's Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine 2Osteotech's Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine 3
(Date:4/24/2014)... Have you ever accidently missed a red light or ... a visible event that you passed by but totally ... for our attention, we can only be aware of ... Beckman Institute Postdoctoral Fellow at the University of Illinois. ... concentrating on obeying traffic signals." , But say there,s ...
(Date:4/24/2014)... attack plants, they often inject harmful proteins into ... natural defenses. However, in some plants, bacteria attack ... potential host. Now, researchers at the University of ... allows the bacteriaknown mostly for attacking tomatoesto invade ... anti-infective treatments that work with food-producing plants to ...
(Date:4/24/2014)... Alison Allan, PhD, a scientist at Western University and ... often spreads or metastasizes to the lung. , Breast ... number two cause of cancer-related deaths among women in ... radiation have a high success rate, but once the ... In particular, the lung is one of the most ...
Breaking Biology News(10 mins):Controlling brain waves to improve vision 2Controlling brain waves to improve vision 3Plants send out signals attracting harmful bacteria, MU study finds 2New study helps to explain why breast cancer often spreads to the lung 2
... The American Association for Cancer Research will host its ... Disparities from Sept. 18-21, 2011, in the Grand Hyatt ... will bring together scientists, survivors, doctors and others to ... treatment methods to better meet the needs of underserved ...
... have employed pheromone-baited bucket traps, canines to sniff out ... to eradicate the coconut rhinoceros beetle (CRB) on Guam ... to these tactics. USDA has given Guam an infusion ... rhino beetle population on island. Aubrey Moore, entomologist and ...
... of American Societies for Experimental Biology (FASEB) announced today ... (HCS). The executive leadership has retained FASEB to ... membership marketing, recruitment, and retention, as well as a ... William Stahl, PhD commented, "HCS is pleased to have ...
Cached Biology News:AACR to host conference on the science of cancer health disparities 2